DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Notification of Renewal Deadline Extension
April 1, 2021

State Surgeon General Scott A. Rivkees issued Emergency Order 21-001 granting licensure renewal extensions Continue reading


NTSB Study on Drug Use Trends in Aviation
March 8, 2021

National Transportation Safety Board issues recommendations to states on prescribing controlled substances for pain and the dangers of operating a vehicle in any mode of transportation Continue reading




Supporting Documents
Medical Degree Verification
NICA FORM
Postgraduate Training Verification